| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Cepeprubart | SelK-2 | Phase 2 Clinical | Selexys | Venous Thromboembolism; Asthma; Pulmonary Disease, Chronic Obstructive | Details |
| Leiolizumab | ALTB-268; AbGn-168H2; AbGn 168H2; AbGn-268 | Phase 2 Clinical | Colitis, Ulcerative | Details | |
| Neihulizumab | AbGn-168; AbGn-168H | Phase 1 Clinical | Abgenomics | Graft vs Host Disease; Psoriasis; Colitis, Ulcerative; Arthritis, Psoriatic | Details |
| SSGJ-617 | SSGJ-617; SSGJ617; 61X; VTX-0811; 617 | Phase 1 Clinical | Verseau Therapeutics Inc | Solid tumours | Details |

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)
メールアドレス
order.jp@acrobiosystems.com
アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8



